Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18529849 | 0.91 | SOD1 (0.35) | AMD1 | |
| SCHEMBL12493499 | 0.83 | AMD1 (0.32) | AMD1MAOB | |
| SCHEMBL15209766 | 0.83 | MAPT (0.34) | — | |
| SCHEMBL4404632 | 0.82 | — | — | |
| SCHEMBL15209164 | 0.81 | NOTUM (0.38) | AMD1 | |
| SCHEMBL1250703 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL1662035 | 0.78 | MAOB (0.49) | MAOB | |
| SCHEMBL5660411 | 0.77 | MEN1 (0.38) | — | |
| SCHEMBL614620 | 0.77 | ALDH1A1 (0.46) | MAOB | |
| SCHEMBL5086981 | 0.75 | MAOB (0.31) | AMD1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802728-B2 | Analgesic compounds, methods, and formulations | ELI LILLY AND COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130225679-A1 | ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS | ELI LILLY AND COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | AMD1 1409/4885MAOB 45/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | AMD1 1409/4885MAOB 45/4885 |
| US-20130225679-A1 | ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS | OPRL1, OPRK1, OPRM1 | AMD1 3267/4885MAOB 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.